Ara-290 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

Ara-290 (also called cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), giving anti-inflammatory and tissue-protective signaling[1][5]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Ara-290 is investigational and not approved by the FDA or any regulator — it has been evaluated through Phase 2 trials only — and is presented for research and educational use only.

Add 2.0 mL bacteriostatic water to one 16 mg vial → 8 mg/mL, a practical concentration for clear insulin-syringe measuring.
4 mg once daily SC in Phase 2 trials; a dose-ranging study evaluated 1, 4 and 8 mg daily for 28 days.
At 8 mg/mL, 1 unit = 0.08 mg (80 mcg); 4 mg = 50 units (0.50 mL) and 8 mg = 100 units (1.00 mL) on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (2 mL = 8 mg/mL)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4	4 mg once daily (SC)	50 units (0.50 mL)
Weeks 5–12 (optional extension)	4 mg once daily (SC)	50 units (0.50 mL)

Reconstitute: Add 2.0 mL bacteriostatic water to one 16 mg vial → final concentration 8 mg/mL.
Documented daily dose: 4 mg once daily SC in Phase 2 trials; a randomized study evaluated 1, 4 and 8 mg daily over 28 days.
Easy measuring: At 8 mg/mL, 1 unit = 0.08 mg (80 mcg) on a U-100 syringe. A 4 mg dose is 50 units (0.50 mL); an 8 mg dose is 100 units (1.00 mL).
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day. The 4 mg/day dose and the 1–4–8 mg dose-ranging arms are real Phase 2 parameters[3][4], but Phase 2 results are early-stage and proven efficacy should not be assumed.
Dose: 8 mg once daily SC for Weeks 1–4 — the upper arm of the Phase 2 dose-ranging study (1, 4 and 8 mg daily for 28 days).
Volume: at 8 mg/mL, 8 mg = 100 units (1.00 mL), which fills a standard 1 mL insulin syringe.
If your syringe holds less than 1 mL, split the 8 mg dose into two injections.

Reconstitution Steps

Draw 2.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Reconstituting the 16 mg vial with 2.0 mL gives 8 mg/mL, keeping the 4 mg dose at a clear 50 units (0.50 mL). Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume a 4-week course (optionally extended to 12 weeks) of once-daily 4 mg injections.

At 4 mg/day, each 16 mg vial covers about 4 days, so plan roughly 7 vials per 4-week month.
4 weeks (4 mg/day): ~7 vials
12 weeks (4 mg/day): ~21 vials
4 weeks (8 mg/day): ~14 vials
Per injection: 1 syringe
4 weeks (once daily): ~28 syringes
12 weeks (once daily): ~84 syringes
Use 2.0 mL per 16 mg vial for reconstitution.
4 weeks (~7 vials): ~14 mL → 2 bottles
12 weeks (~21 vials): ~42 mL → 5 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
4 weeks (once daily): ~56 swabs → 1 box

Protocol Overview

A concise summary of the once-daily regimen, drawn from published Phase 2 trial parameters.

▪Goal: Support small-fiber nerve integrity and modulate inflammatory signaling via selective IRR activation — explored in Phase 2 trials, not established as proven[5][6].
▪Schedule: Once-daily subcutaneous injections; neuropathy trials ran 4 weeks, with some studies up to 12 weeks.
▪Dose Range: 4 mg/day is the documented trial dose; dose-ranging arms studied 1 mg and 8 mg/day.
▪Reconstitution: 2.0 mL bacteriostatic water per 16 mg vial gives 8 mg/mL for straightforward unit measurements.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily approach based on documented Phase 2 trial doses.

▪Standard dose: 4 mg subcutaneously once daily — the dose documented in human Phase 2 trials.
▪High-dose option: 8 mg subcutaneously once daily for 28 days — the upper dose-ranging arm.
▪Measurement: At 8 mg/mL, 4 mg = 0.50 mL (50 units); 8 mg = 1.00 mL (100 units).
▪Cycle length: 4 weeks in neuropathy trials; some studies extended to 12 weeks.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Ara-290 is not approved by the FDA or any regulator — it is investigational and has only reached Phase 2. Its FDA Orphan Drug designation for sarcoidosis-associated neuropathy is a development incentive, not an approval[10].

How This Works

Ara-290 (cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B region of erythropoietin (EPO)[1][2]. It was deliberately engineered to be non-erythropoietic — it does not raise red blood cells, avoiding the hematocrit risks of full-length EPO.

Its mechanism is selective activation of the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the beta-common receptor (CD131). Engaging this receptor triggers cytoprotective and anti-inflammatory signaling in injured tissue without stimulating red-blood-cell production[5][6].
In Phase 2 trials, Ara-290 has been studied for small-fiber neuropathy in sarcoidosis, diabetic neuropathy and neuropathic pain, with reports of improved neuropathic symptom scores and corneal nerve-fiber measures[11]. These are early-stage findings and do not establish proven efficacy[12].
Important caveat: Ara-290 has been evaluated only through Phase 2/2b trials; it has not completed Phase 3 and is not approved by the FDA or any regulator. It holds FDA Orphan Drug designation for sarcoidosis-associated neuropathy — a development incentive, not an approval. Any benefit claims should be read as early-stage hypotheses.
Ara-290 is not an approved medicine. It is an investigational research compound presented here for research and educational purposes only.

Lifestyle Factors

General habits that support overall health alongside the protocol.

▪Nutrition: Keep a balanced, nutrient-dense diet to support overall tissue health.
▪Activity & rest: Pair appropriate movement with adequate rest and avoid overexertion.
▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall healing.

Potential Benefits & Side Effects

What early-phase clinical research describes; evidence is limited to Phase 2 and individual results vary.

▪Small-fiber neuropathy (Phase 2): Trials reported improved neuropathic symptom scores and corneal nerve-fiber measures, suggesting tissue-protective signaling[5][6].
▪Anti-inflammatory signaling: IRR activation has been linked to a shift from pro-inflammatory toward tissue-protective signaling in preclinical and early clinical work[11].
▪Non-erythropoietic: By design it does not stimulate erythropoiesis, avoiding the hematocrit/thrombotic risks associated with EPO.
▪Note on evidence: These findings are early-stage — Ara-290 has only reached Phase 2/2b and proven efficacy has not been established[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Limited long-term data: Human safety data is limited to Phase 2 exposure, so caution and monitoring are advised.
▪Not approved: Ara-290 is investigational and not approved for human use; orphan-drug status is not an approval.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for Ara-290 10mg.

Ara-290 (16 mg Vial) Dosage Protocol Open source
1 Molecular Medicine ARA 290, a peptide derived from the helix-B of erythropoietin, that selectively activates the innate repair receptor. View Source ↗ Open source
2 Molecular Medicine (PubMed) Cibinetide (ARA 290) is non-erythropoietic and engineered to avoid the hematocrit effects of erythropoietin. View Source ↗ Open source
3 Journal of Diabetes Science and Technology Phase 2 study of cibinetide (ARA 290) 4 mg/day subcutaneously in patients with diabetic neuropathic pain. View Source ↗ Open source
4 Molecular Medicine (Phase 2b) Randomized dose-ranging trial of cibinetide (1, 4 and 8 mg daily for 28 days) in sarcoidosis small-fiber neuropathy. View Source ↗ Open source
5 Journal of Internal Medicine (PubMed) Cibinetide improves small-fiber neuropathy symptoms and corneal nerve-fiber measures in early clinical studies. View Source ↗ Open source
6 Molecular Medicine (PubMed) Mechanism of the innate repair receptor (EPOR/CD131 heterodimer) and its tissue-protective, anti-inflammatory signaling. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 U.S. FDA Orphan Drug Designations FDA Orphan Drug designation database — orphan status is a development incentive, not a marketing approval. View Source ↗ Open source
11 Journal of Internal Medicine Cibinetide reduces neuropathic pain and improves quality-of-life measures in Phase 2 sarcoidosis trials. View Source ↗ Open source
12 Frontiers in Pharmacology (PubMed) Review of ARA 290 / cibinetide development across early-phase trials; efficacy remains investigational. View Source ↗ Open source
13 ClinicalTrials.gov Registered Phase 2 trials of cibinetide (ARA 290); no Phase 3 program has been completed and the peptide is not approved. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Prime Lab Peptides Research peptide supplier — purity specifications and certificates of analysis. View Source ↗ Open source

Contents